Ipsen Shares New Dysport Data at Physical Medicine and Rehabilitation Conference
Ipsen Biopharmaceuticals, an affiliate of Ipsen, announced that five abstracts discussing Dysport (abobotulinumtoxinA) were presented at the American Academy of Physical Medicine and Rehabilitation (AAPM&R) Annual Assembly, held Oct. 12-15 in Denver, Colorado. Dysport, a botulinum toxin product, is approved for treatment of spasticity, or shaking, in adult patients, which…